Last reviewed · How we verify
NCT04795362: SKinDCI
S100B Kinetic During the Occurrence and Treatment of Delayed Cerebral Ischaemia After a Subarachnoid Haemorrhage.
trial testing blood sample in Subarachnoid Hemorrhage in 50 participants. Completed in 17 June 2024.
17 June 2024
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 20 July 2021 |
| Primary completion | 17 June 2024 |
| Estimated completion | 17 June 2024 |
| Sites | 2 locations across France |
Drugs / interventions tested
- blood sample — full drug profile →
Conditions studied
- Subarachnoid Hemorrhage — all drugs for Subarachnoid Hemorrhage →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
18 and older, any sex, with Subarachnoid Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nearly half of the survivors of subarachnoid haemorrhage (SAH) retain irreversible neurological damage resulting from the early lesions associated with the initial bleeding, and the occurrence of possible delayed cerebral ischaemia (DCI). The early diagnosis of the occurrence of an DCI is therefore a major challenge in order to optimise management before irreversible lesions are formed. However, the means of diagnosis are often not available, and up to a third of DCI are discovered on follow-up images when the lesions are already present. Among the markers of brain injury, S100 calcium-binding protein B (S100B) is an astrocyte protein released into the bloodstream at the time of the appearance of a brain lesion. Its short half-life makes it a prime candidate for patient follow-up to diagnose a new ischemic lesion and assess the effectiveness of its management. Among the elements at the origin of DCI, the occurrence of proximal vasospasm is the main element on which we can have a therapeutic action. The strategy implemented in the department consists of performing a mechanical angioplasty when proximal vasospasm is detected with a decrease in downstream cerebral perfusion. Nevertheless the benefit of this therapeutic action is discussed and there is currently no early marker of the effectiveness of this procedure.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Advances in development of biomarkers for brain damage and ischemia.
Karimova D, Rostami E, Chubarev VN, Tarasov VV, et al · · 2024 · cited 5× · PMID 39001884 · DOI 10.1007/s11033-024-09708-x -
Activity and Heterogeneity of Astrocytes in Neurological Diseases: Molecular Mechanisms and Therapeutic Targets.
Mao S, Qiao R, Wang Q, Shen L, et al · · 2025 · cited 1× · PMID 40859959 · DOI 10.1002/mco2.70329
Verify or expand the search:
- PubMed search for NCT04795362
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blood sample
Trials testing the same drug.
- NCT07370792 — Contribution of Optical Genome Mapping (OGM) in the Diagnosis of Multiple Congenital Malformations With or Without Intel · NA · recruiting
- NCT07273331 — Nursing Needs of Patients With Cirrhosis · enrolling by invitation
- NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
- NCT06968598 — Analysis of Early Neurodevelopmental Alterations in Bipolar Disorder Based on Cortical Organoid Models · NA · not yet recruiting
- NCT07332702 — Long Read Analysis in Spinal Muscular Atrophy - LOREASI · NA · recruiting
Other recruiting trials for Subarachnoid Hemorrhage
Currently open trials in the same condition.
- NCT06797765 — Optical Coherence Tomography Angiography in Neurological Disease · recruiting
- NCT06866210 — Risk Analysis of Intracranial Aneurysm Rupture Through Social Determinants of Health · active not recruiting
- NCT06797752 — Effect of the Stellate Ganglion Block on the Retinal Microcirculation · recruiting
- NCT06192342 — Ventilatory Parameters in Acute Neurological Injury · recruiting
- NCT04459806 — Intracranial PrEssure Time dOse (ImPETO) · recruiting
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04795362 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 5 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04795362.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing